EirGen announces new agreement with Corepharma, US Trade Mission, New York

EirGen Pharma Ltd., a private Irish healthcare company and Corepharma LLC (“Corepharma”), announced today they have agreed to expand on their collaboration to date to develop and commercialize a number of specialised pharmaceutical products for sale in the United States.

Under the terms of the agreement, EirGen Pharma will exclusively develop and commercially supply these products to Corepharma for the US market. The companies have agreed to collaborate for the development and commercialisation of two products with a current market value in excess of $300 million. The companies are also evaluating the potential of developing another three products with current US sales of over $1.5 Billion.

Gregory Young, CEO of Corepharma stated that “The addition of new products into our collaboration with EirGen Pharma is a measure of our confidence in their ability to achieve the desired milestones. It is also a reflection of our continuing commitment to bring therapeutically important, high value products to the US market.” Patsy Carney, CEO of EirGen Pharma commented that “We have an established relationship with Corepharma and this latest opportunity is a measure of the success of the existing collaborations. We look forward to continuing to work with Corepharma to successfully commercialise the full portfolio of products.”